Intermonte analyst Giorgio Tavolini maintained a Buy rating on PharmaNutra SpA on September 9 and set a price target of €84.00.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Giorgio Tavolini has given his Buy rating due to a combination of factors that highlight PharmaNutra SpA’s strong performance and growth potential. The company reported robust first-half results for 2025, showcasing double-digit revenue growth driven by both international and domestic markets. A significant contributor to this growth was the successful launch of Sidevit B12, which generated impressive sales figures in its debut period.
Furthermore, the company’s strategic investments in new business lines, particularly in the US and China, are expected to yield substantial returns in the coming years. Despite short-term margin pressures due to these investments, management remains confident in maintaining healthy margins and achieving breakeven in key markets soon. Tavolini’s confidence in the stock is also supported by the potential for significant sales expansion in the US and China, which could lead to a substantial increase in the stock’s value, offering a promising upside for investors.
According to TipRanks, Tavolini is ranked #7288 out of 9983 analysts.
In another report released on September 9, TP ICAP MIDCAP also maintained a Buy rating on the stock with a €74.00 price target.